Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 18, 2025 04:45 ET | Source: BioNTech SE

BioNTech schließt Übernahme von CureVac N.V. samt damit verbundener Nachangebotsfrist ab und stärkt so die einzigartige Position im mRNA-Feld

BioNTech hat das Umtauschangebot zur Übernahme von CureVac abgeschlossenDie Übernahme von CureVac ergänzt BioNTechs Fähigkeiten und unternehmenseigene Technologien im Bereich mRNA-Design,...
December 18, 2025 04:45 ET | Source: BioNTech SE

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

BioNTech has completed its exchange offer to acquire CureVacAcquisition complements BioNTech’s capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturingIn...
December 17, 2025 13:00 ET | Source: DelveInsight Business Research LLP

BTK Inhibitors Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

New York, USA, Dec. 17, 2025 (GLOBE NEWSWIRE) -- BTK Inhibitors Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight Overall, BTK...
December 11, 2025 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry’s broadest in vitro diagnostic menu

With this approval, Roche’s automated mass spectrometry platform now offers the industry’s broadest in vitro diagnostic menu with 39 tests, including tests for therapeutic drug monitoring for...
December 10, 2025 08:15 ET | Source: F. Hoffmann-La Roche Ltd

Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer

Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant endocrine therapy advance in over 20 years1-3Transformational...
December 09, 2025 07:00 ET | Source: BioNTech SE

Erste Ergebnisse aus BioNTechs und BMS’ globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig zeigten ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem dreifach negativem Brustkrebs

Zwischenergebnisse der globalen klinischen Phase-2-Studie bei lokal fortgeschrittenem/metastasiertem dreifach negativem Brustkrebs (triple-negative breast cancer, „TNBC“) zeigten eine ermutigende...
December 09, 2025 07:00 ET | Source: BioNTech SE

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus...
December 09, 2025 01:10 ET | Source: F. Hoffmann-La Roche Ltd

Roche launches new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark

The new PCR test aids in the diagnosis of infectious causes of vaginitis through the detection of bacteria associated with bacterial vaginosis and yeast associated with candida vaginitis. The test...
December 09, 2025 01:00 ET | Source: F. Hoffmann-La Roche Ltd

European Commission approves Roche’s Gazyva/Gazyvaro for adults with active lupus nephritis

Approval based on phase II NOBILITY and phase III REGENCY studies showing superiority of Gazyva/Gazyvaro over standard therapy alone1,2Gazyva/Gazyvaro is the only anti-CD20 antibody to demonstrate a...
December 08, 2025 16:30 ET | Source: F. Hoffmann-La Roche Ltd

Roche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas

Lunsumio in combination with lenalidomide may offer an effective treatment in relapsed or refractory follicular lymphoma based on first data from single-arm US cohort of phase III CELESTIMO study1Data...